SUPERNUS PHARMACEUTICALS INC's ticker is SUPN and the CUSIP is 868459108. A total of 224 filers reported holding SUPERNUS PHARMACEUTICALS INC in Q3 2021. The put-call ratio across all filers is 0.12 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $1,546 | -43.7% | 57,783 | -28.3% | 0.00% | -100.0% |
| Q1 2024 | $2,748 | -7.6% | 80,576 | -21.6% | 0.00% | 0.0% |
| Q4 2023 | $2,975 | +96.9% | 102,799 | +87.4% | 0.00% | 0.0% |
| Q3 2023 | $1,511 | -6.6% | 54,844 | +1.9% | 0.00% | 0.0% |
| Q2 2023 | $1,617 | -1.4% | 53,823 | +19.0% | 0.00% | 0.0% |
| Q1 2023 | $1,640 | +3.0% | 45,238 | +1.4% | 0.00% | 0.0% |
| Q4 2022 | $1,592 | -99.9% | 44,602 | -12.4% | 0.00% | -50.0% |
| Q3 2022 | $1,723,000 | +20.4% | 50,939 | +2.9% | 0.00% | +100.0% |
| Q2 2022 | $1,431,000 | -34.0% | 49,490 | -26.2% | 0.00% | -50.0% |
| Q1 2022 | $2,167,000 | -52.1% | 67,046 | -56.8% | 0.00% | +100.0% |
| Q4 2021 | $4,526,000 | +171.5% | 155,196 | +148.3% | 0.00% | 0.0% |
| Q3 2021 | $1,667,000 | +57.6% | 62,500 | +81.9% | 0.00% | – |
| Q2 2021 | $1,058,000 | -62.1% | 34,368 | -67.8% | 0.00% | -100.0% |
| Q1 2021 | $2,795,000 | -7.9% | 106,758 | -11.5% | 0.00% | 0.0% |
| Q4 2020 | $3,036,000 | -6.4% | 120,687 | -22.5% | 0.00% | 0.0% |
| Q3 2020 | $3,244,000 | -2.5% | 155,628 | +11.1% | 0.00% | -33.3% |
| Q2 2020 | $3,327,000 | +97.8% | 140,093 | +49.9% | 0.00% | +200.0% |
| Q1 2020 | $1,682,000 | -71.5% | 93,442 | -62.4% | 0.00% | -66.7% |
| Q4 2019 | $5,893,000 | +37.4% | 248,435 | +59.1% | 0.00% | 0.0% |
| Q3 2019 | $4,289,000 | +96.9% | 156,128 | +137.2% | 0.00% | +200.0% |
| Q2 2019 | $2,178,000 | -28.2% | 65,829 | -24.0% | 0.00% | -50.0% |
| Q1 2019 | $3,035,000 | +28.0% | 86,622 | +21.3% | 0.00% | 0.0% |
| Q4 2018 | $2,372,000 | -41.8% | 71,382 | -11.8% | 0.00% | -33.3% |
| Q3 2018 | $4,075,000 | +135.3% | 80,943 | +179.5% | 0.00% | +200.0% |
| Q2 2018 | $1,732,000 | +55.6% | 28,962 | +19.1% | 0.00% | 0.0% |
| Q1 2018 | $1,113,000 | +147.3% | 24,319 | +115.7% | 0.00% | – |
| Q4 2017 | $450,000 | +166.3% | 11,272 | +167.9% | 0.00% | – |
| Q3 2017 | $169,000 | -44.6% | 4,208 | -40.4% | 0.00% | – |
| Q2 2017 | $305,000 | +23.5% | 7,055 | -10.8% | 0.00% | – |
| Q1 2017 | $247,000 | +341.1% | 7,909 | +255.6% | 0.00% | – |
| Q4 2016 | $56,000 | -88.8% | 2,224 | -89.0% | 0.00% | -100.0% |
| Q3 2016 | $501,000 | +20.7% | 20,287 | -0.5% | 0.00% | 0.0% |
| Q2 2016 | $415,000 | +23.9% | 20,383 | -8.8% | 0.00% | 0.0% |
| Q1 2016 | $335,000 | -20.6% | 22,349 | -31.1% | 0.00% | 0.0% |
| Q4 2015 | $422,000 | -72.2% | 32,419 | -70.1% | 0.00% | -50.0% |
| Q3 2015 | $1,518,000 | +6800.0% | 108,324 | +8213.4% | 0.00% | – |
| Q2 2015 | $22,000 | -87.4% | 1,303 | -91.1% | 0.00% | – |
| Q1 2015 | $175,000 | +337.5% | 14,644 | +194.8% | 0.00% | – |
| Q4 2014 | $40,000 | -70.4% | 4,968 | -70.5% | 0.00% | – |
| Q3 2014 | $135,000 | +32.4% | 16,862 | +65.1% | 0.00% | – |
| Q2 2014 | $102,000 | -54.7% | 10,211 | -63.6% | 0.00% | – |
| Q1 2014 | $225,000 | +129.6% | 28,048 | +99.8% | 0.00% | – |
| Q4 2013 | $98,000 | -24.0% | 14,035 | -23.8% | 0.00% | – |
| Q3 2013 | $129,000 | +460.9% | 18,416 | +416.4% | 0.00% | – |
| Q2 2013 | $23,000 | – | 3,566 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 297,500 | $17,478,000 | 3.94% |
| ASHFORD CAPITAL MANAGEMENT INC | 1,124,405 | $36,341,000 | 3.91% |
| ARMISTICE CAPITAL, LLC | 3,100,000 | $100,192,000 | 1.94% |
| S&T BANK/PA | 316,326 | $10,224,000 | 1.54% |
| Bruce & Co., Inc. | 222,105 | $7,178,000 | 1.47% |
| MESIROW FINANCIAL INVESTMENT MANAGEMENT - Fixed Income | 379,875 | $12,278,000 | 1.36% |
| RICE HALL JAMES & ASSOCIATES, LLC | 854,949 | $27,632,000 | 1.10% |
| Soleus Capital Management, L.P. | 251,000 | $8,112,000 | 1.05% |
| Parkman Healthcare Partners LLC | 108,954 | $3,521,000 | 1.03% |
| Aristotle Capital Boston, LLC | 1,258,067 | $40,661,000 | 1.03% |